Gary A Ulaner
Overview
Explore the profile of Gary A Ulaner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
153
Citations
3076
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parihar A, Vaz S, Sutcliffe S, Pant N, Schoones J, Ulaner G
J Nucl Med
. 2025 Mar;
PMID: 40081952
F-fluoroestradiol (F-FES) PET/CT has been investigated as a potential biomarker to predict response to endocrine therapies in patients with estrogen receptor (ER)-positive breast cancer. Although previous findings were promising, most...
2.
Ulaner G, Lewis J, Landgren O
J Nucl Med
. 2025 Jan;
66(3):482.
PMID: 39884767
No abstract available.
3.
Reddy R, Ulaner G
Clin Nucl Med
. 2025 Jan;
50(4):358-359.
PMID: 39853177
A 64-year-old man with newly diagnosed prostate cancer underwent 18 F-Piflufolastat PET/CT. Radiotracer avidity localized to the primary prostate malignancy and to a left rib (SUV max , 9.0). The...
4.
Vaz S, Groheux D, van Nijnatten T, Antunovic L, Cardoso F, Mottaghy F, et al.
Eur J Nucl Med Mol Imaging
. 2024 Dec;
52(3):801-805.
PMID: 39706898
No abstract available.
5.
Groheux D, Vaz S, Poortmans P, Mann R, Ulaner G, Cook G, et al.
Breast
. 2024 Sep;
78:103806.
PMID: 39303572
Purpose: The recently released EANM/SNMMI guideline, endorsed by several important clinical and imaging societies in the field of breast cancer (BC) care (ACR, ESSO, ESTRO, EUSOBI/ESR, EUSOMA), emphasized the role...
6.
Ulaner G, VanderMolen L, Li G, Ferreira D
Radiology
. 2024 Jul;
312(1):e233408.
PMID: 39078299
Background Somatostatin receptors, and specifically somatostatin receptor type 2 (SSTR2), have primarily been associated with neuroendocrine tumors and have revolutionized the imaging and therapy of patients with these tumors. SSTR2...
7.
Ulaner G, Silverstein M, Nangia C, Tetef M, Vandermolen L, Coleman C, et al.
JAMA Netw Open
. 2024 Jul;
7(7):e2423435.
PMID: 39058489
Importance: There are insufficient data comparing 16α-18F-fluoro-17β-estradiol (FES) positron emission tomography (PET) computed tomography (CT) with standard-of-care imaging (SOC) for staging locally advanced breast cancer (LABC) or evaluating suspected recurrence....
8.
Basaco Bernabeu T, Mansi R, Del Pozzo L, Zanger S, Gaonkar R, McDougall L, et al.
J Nucl Med
. 2024 Jul;
65(9):1427-1434.
PMID: 39025646
The demand for PET tracers that target prostate-specific membrane antigen (PSMA) continues to increase. Meeting this demand with approved Ga- and F-labeled PSMA tracers is challenging outside of major urban...
9.
10.
Kuo P, Esposito G, Ulaner G, Yoo D, Zukotynski K, Ravizzini G, et al.
J Nucl Med
. 2024 Jun;
65(8):1239-1243.
PMID: 38871390
Interreader and intrareader reproducibility of F-flotufolastat PET/CT scans in newly diagnosed and recurrent prostate cancer patients was assessed from masked image evaluations from two phase 3 studies. F-flotufolastat PET/CT images...